MedTrace Logo

Efficacy and Safety of Vaccination Against COVID-19 in Neuromuscular Patients

NCT05311904 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1388

Last updated 2023-10-06

No results posted yet for this study

Summary

The frequency of severe forms of COVID-19 is higher in people with neuromuscular disease and in severe cases and long hospital stays, the disability of some neuromuscular patients may worsen due to prolonged bed rest . Finally, the symptoms of certain diseases such as myasthenia gravis can worsen after an infection such as COVID-19.

Thanks to an unprecedented research effort, vaccines are now available and others still in development. The first studies published in medical journals are reassuring about the efficacy and safety of these vaccines. However, they have been studied in the general population and we do not yet have specific information in neuromuscular patients.

This is the reason why the Va-C-NEMUS observatory was launched.

Conditions

Interventions

OTHER

Survey

1 initial questionnaire and 1 monthly follow-up questionnaire for 11 months

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Guilhem SOLE, MD · Université Hospital, Bordeaux

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-11
Primary Completion
2023-02-03
Completion
2023-02-03

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05311904 on ClinicalTrials.gov